EA201691555A1 - Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени - Google Patents

Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени

Info

Publication number
EA201691555A1
EA201691555A1 EA201691555A EA201691555A EA201691555A1 EA 201691555 A1 EA201691555 A1 EA 201691555A1 EA 201691555 A EA201691555 A EA 201691555A EA 201691555 A EA201691555 A EA 201691555A EA 201691555 A1 EA201691555 A1 EA 201691555A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
dystrophies
liver
fatial
prevention
Prior art date
Application number
EA201691555A
Other languages
English (en)
Russian (ru)
Inventor
Кейт С. Усискин
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201691555A1 publication Critical patent/EA201691555A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201691555A 2014-01-31 2015-01-30 Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени EA201691555A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934003P 2014-01-31 2014-01-31
US201461948882P 2014-03-06 2014-03-06
PCT/US2015/013644 WO2015116880A1 (en) 2014-01-31 2015-01-30 Methods for the treatment and prevention of renal disorders and fatty liver disorders

Publications (1)

Publication Number Publication Date
EA201691555A1 true EA201691555A1 (ru) 2017-01-30

Family

ID=52544570

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691555A EA201691555A1 (ru) 2014-01-31 2015-01-30 Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени

Country Status (11)

Country Link
US (3) US20160339047A1 (cg-RX-API-DMAC7.html)
EP (1) EP3099328A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017504649A (cg-RX-API-DMAC7.html)
KR (1) KR20160107344A (cg-RX-API-DMAC7.html)
CN (3) CN105939728A (cg-RX-API-DMAC7.html)
AU (2) AU2015210898A1 (cg-RX-API-DMAC7.html)
CA (1) CA2938406A1 (cg-RX-API-DMAC7.html)
EA (1) EA201691555A1 (cg-RX-API-DMAC7.html)
IL (1) IL246779A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016010011A (cg-RX-API-DMAC7.html)
WO (1) WO2015116880A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018113437A (ru) * 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
CN108289963B (zh) * 2015-11-06 2023-08-29 营养Dna控股有限公司 用于测试对于口服葡萄糖负荷响应的方法和产品
GB201614455D0 (en) * 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
TWI835735B (zh) * 2017-06-12 2024-03-21 比利時商健生藥品公司 減少或預防第ii型糖尿病患者中心血管事件之方法
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
LT3716979T (lt) 2017-11-30 2025-07-10 Idorsia Pharmaceuticals Ltd 4-pirimidinsulfamido darinio derinys su sglt-2 inhibitoriumi, skirtas su endotelinu susijusių ligų gydymui
CA3134786A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv Methods for treating subjects with chronic kidney disease
CN110051851A (zh) * 2019-05-31 2019-07-26 江苏苏中药业集团股份有限公司 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合
WO2022036506A1 (zh) * 2020-08-17 2022-02-24 天津睿创康泰生物技术有限公司 Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
AU2021368618B2 (en) * 2020-10-30 2025-02-27 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CN116234545A (zh) * 2020-11-19 2023-06-06 北京睿创康泰医药研究院有限公司 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途
JP2024094532A (ja) 2022-12-28 2024-07-10 キヤノン株式会社 撮像設定装置および撮像装置
KR20240126452A (ko) * 2023-02-10 2024-08-21 가천대학교 산학협력단 칸데사르탄 또는 아질사르탄을 포함하는 조성물의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980703647A (ko) * 1995-04-07 1998-12-05 베르너발데크 베나제프릴 또는 베나제프릴라트 및 발사르탄을 함유하는조성물
CN104109155A (zh) 2003-08-01 2014-10-22 田边三菱制药株式会社 新颖化合物
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916476A2 (pt) * 2008-12-01 2016-02-16 Invasc Therapeutics Inc composição, método de tratamento para um distúrbio relacionado ao sistema renina-angiotensina-aldosterona, método para reduzir a resistência à insulina, método para tratar um distúrbio relacionado à síndrome metabólica
CN102421433B (zh) * 2009-03-26 2015-09-23 阿贾伊·古普塔 用于治疗肾病的组合物和方法
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
MX366925B (es) * 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
BR112013009531A2 (pt) * 2010-11-11 2016-07-19 Redx Pharma Ltd derivados de fármaco
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy

Also Published As

Publication number Publication date
CN105939728A (zh) 2016-09-14
AU2015210898A1 (en) 2016-07-28
US20160339047A1 (en) 2016-11-24
EP3099328A1 (en) 2016-12-07
JP2017504649A (ja) 2017-02-09
WO2015116880A1 (en) 2015-08-06
CN113144204A (zh) 2021-07-23
KR20160107344A (ko) 2016-09-13
CA2938406A1 (en) 2015-08-06
MX2016010011A (es) 2016-10-07
JP2020090511A (ja) 2020-06-11
US20180344756A1 (en) 2018-12-06
IL246779A0 (en) 2016-08-31
US20210121492A1 (en) 2021-04-29
AU2020281039A1 (en) 2021-01-07
CN113082021A (zh) 2021-07-09

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2016010011A (es) Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201790398A1 (ru) Способы лечения заболевания печени
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
TW201613578A (en) Pharmaceutical combinations
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2